JP2025504447A5 - - Google Patents

Info

Publication number
JP2025504447A5
JP2025504447A5 JP2024542395A JP2024542395A JP2025504447A5 JP 2025504447 A5 JP2025504447 A5 JP 2025504447A5 JP 2024542395 A JP2024542395 A JP 2024542395A JP 2024542395 A JP2024542395 A JP 2024542395A JP 2025504447 A5 JP2025504447 A5 JP 2025504447A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
acid
pharmaceutical composition
cardiovascular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024542395A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025504447A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2023/071973 external-priority patent/WO2023134732A1/en
Publication of JP2025504447A publication Critical patent/JP2025504447A/ja
Publication of JP2025504447A5 publication Critical patent/JP2025504447A5/ja
Pending legal-status Critical Current

Links

JP2024542395A 2022-01-17 2023-01-12 アスピリン及びその他のnsaidの高透過プロドラッグによる心血管疾患の予防又は治療 Pending JP2025504447A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2022/072270 2022-01-17
CN2022072270 2022-01-17
PCT/CN2023/071973 WO2023134732A1 (en) 2022-01-17 2023-01-12 Prevention or treatment of cardiovascular diseases with high penetration prodrugs of aspirin and other nsaids

Publications (2)

Publication Number Publication Date
JP2025504447A JP2025504447A (ja) 2025-02-12
JP2025504447A5 true JP2025504447A5 (cg-RX-API-DMAC7.html) 2026-02-17

Family

ID=87280122

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024542395A Pending JP2025504447A (ja) 2022-01-17 2023-01-12 アスピリン及びその他のnsaidの高透過プロドラッグによる心血管疾患の予防又は治療

Country Status (10)

Country Link
US (1) US20250099491A1 (cg-RX-API-DMAC7.html)
EP (1) EP4465993A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025504447A (cg-RX-API-DMAC7.html)
KR (1) KR20250005055A (cg-RX-API-DMAC7.html)
CN (1) CN118632699A (cg-RX-API-DMAC7.html)
AU (1) AU2023206720A1 (cg-RX-API-DMAC7.html)
CA (1) CA3252370A1 (cg-RX-API-DMAC7.html)
IL (1) IL314290A (cg-RX-API-DMAC7.html)
TW (1) TW202339711A (cg-RX-API-DMAC7.html)
WO (1) WO2023134732A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118373749A (zh) * 2024-04-29 2024-07-23 四川施成收生态科技有限公司 一种含有2-羟基苯甲酸-2-(二乙氨基)乙酯结构的化合物制备及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH399486A (fr) 1962-10-02 1965-09-30 Biosedra Lab Procédé de préparation de nouvelles salicylamides
AU2006346195B2 (en) 2006-07-09 2013-03-07 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of aspirin
CN101500983B (zh) 2006-07-26 2015-09-16 于崇曦 具有快速皮肤穿透速度的带正电荷的水溶性二氟尼柳及相关化合物的前药
HK1207562A1 (en) 2012-01-18 2016-02-05 苏州泰飞尔医药有限公司 High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions
BR112015022896B1 (pt) * 2013-03-15 2022-08-23 Chongxi Yu Composto de fármacos de alta penetração, composição farmacêutica e seus usos para o tratamento de doenças de parkinson

Similar Documents

Publication Publication Date Title
EP3259271B1 (en) Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof
DE60219595T2 (de) Verfahren zur behandlung von erkrankungen mit malonyl coa-decarboxylase-inhibitoren
NZ756256A (en) Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
US20090023712A1 (en) Pharmaceutical Compositions for the Treatment of Attention Deficit Hyperactivity Disorder Comprising Flibanserin
MXPA04001153A (es) Derivados de amidina para tratar la amiloidosis.
SG172981A1 (en) Methods for treating acute myocardial infarctions and associated disorders
JP2022539329A5 (cg-RX-API-DMAC7.html)
AU2014340182A1 (en) Cromolyn derivatives and related methods of imaging and treatment
KR102543227B1 (ko) 폐고혈압을 치료하기 위한 병용 요법
JP2016514141A5 (cg-RX-API-DMAC7.html)
JP2023553253A (ja) 重水素化jak阻害剤による脱毛障害の治療のためのレジメン
AU2021288679A1 (en) Methods for treating or preventing chronic kidney disease
ES2349471T3 (es) Derivados de azabiciclooctan-3-ona y su uso.
JPH06504277A (ja) 新規な3,4−ジヒドロイソキノリン誘導体並びに炭素環式及び複素環式の縮合ジヒドロピリジンの新規な医薬としての使用
CN100395236C (zh) 用于治疗神经病的哌嗪和哌啶衍生物
PL182742B1 (pl) Kombinacja związków do leczenia infekcji HIV i/lub AIDS, środek farmaceutyczny oraz zastosowanie kombinacji związków do wytwarzania leku do leczenia infekcji HIV i/lub AIDS
JP4658919B2 (ja) フェニルカルボン酸アミドおよびIKrチャンネル遮断剤の組み合わせならびに心房性不整脈を処置するためのその使用
ES2671732T3 (es) Procedimiento mejorado para preparar un compuesto intermedio del inhibidor de proteasa macrocíclico TMC 435
WO2019070709A1 (en) COMPOUNDS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS
EP4465993A1 (en) Prevention or treatment of cardiovascular diseases with high penetration prodrugs of aspirin and other nsaids
AU2021202066A1 (en) Use of iminosugar compound in preparation of anti-sars-cov-2 virus drug
SK6842000A3 (en) A mixture of inhibitors, a combined pharmaceutical composition comprising the same and use thereof
CN117143040B (zh) 一种环丁烯二酮基苯并恶唑衍生物及其制备方法和应用
US20130217778A1 (en) Methods and compositions for the improvement of skeletal muscle function in a mammal
JP2003528850A (ja) 血管形成および腫瘍成長の阻害